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Abstract
The outcome of Toxocara canis infections in the canine host depends on the migratory pathway of parasite larvae (somatic or
tracheal) which is considered to be related to the host’s age and its immune status. However, field studies attest high prevalences
of patent T. canis infections in adult animals. The controlled induction of patent infections with low doses of embryonated eggs
was investigated in 18 beagles in a 7-month study until their 16th life month. The animals were assigned to three groups, each
consisting of three vertically infected dogs (with a short patent infection as pups before anthelmintic treatment) and three
helminth-free dogs. At study days 10 and 40, the animals of groups 1 and 3 were given each 100 embryonated T. canis eggs. In
each case, group 1 was treated 10 days post-infection with Milbemax1, while dogs of group 3 remained untreated. Control
group 2 was not experimentally infected but treated as group 1. Two weeks after first egg administration, a sharp increase of
specific antibody reactions in ELISA and increased eosinophilic counts indicated larval invasion in all infected dogs. 42–56 days
following first infection, patent infections were detected coproscopically in all animals of group 3, but in none of the uninfected
dogs (group 2) or the infected and treated dogs (group 1). Following a 3-month observation period, all animals of the three
groups were treated with piperazine citrate to eliminate intestinal infections and all were administered 100 embryonated eggs.
Subsequently, patent infections developed in animals of all groups: in one of the infected and treated animals of group 1, in five
of the so far not infected control group 2 and in four of the dogs with previous patent infections (group 3). Susceptibility to
patent infections was not significantly altered in T. canis-free dogs compared to dogs with previous patent infection (vertically
acquired or experimentally induced). However, dogs of group 1 treated with Milbemax1 after repeated egg administration
developed a significantly increased resistance to patent infections as compared to control dogs (group 2). Observed prepatency
periods were between 40 and 56 days and did not differ in the three groups. Even in urban areas, facing high infection pressure
with Toxocara eggs maintained by a high dog and fox population, dogs of all ages are at risk to develop patent T. canis
infections.
# 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Toxocara canis (Werner, 1782) is one of the most
frequently found gastrointestinal helminths of domes-
tic and wild canids (Overgaauw, 1997; Maizels et al.,
2006) and the agent of Toxocarosis, a serious
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zoonotic disease in humans (Despommier, 2003).
Infection of the canid arises from vertical larval
transmission (intrauterine or lactogenic), from inges-
tion of embryonated eggs from the environment or
ingestion of larvae, e.g., from paratenic hosts like
rodent prey animals (Overgaauw, 1997; Lloyd, 1998).
Infection source, age of the dog, and number of
ingested eggs determine the migratory pathway of the
parasite in the dog. Hormonal and immunological
status, breed and gender are further factors considered
critical for the outcome of larval migration (Lloyd,
1998). The tracheal migration pattern leads to the
development of adult and patent worms in the
intestine. This liver-lung-trachea-oesophagus route
is mainly attributed to young animals (Greve, 1971).
When adult dogs ingest embryonated eggs, the
majority of larvae migrate to somatic tissues, leading
to their accumulation preferentially in muscles and
kidneys, liver and central nervous system (Dubey,
1978; Manhardt and Stoye, 1981). Only in a
proportion of adult dogs some larvae undergo tracheal
migration resulting in intestinal infection (Lloyd,
1998). Specifications of the dog’s age at the transition
point from tracheal to somatic pathway differ among
authors between about 1–2 months (Sprent, 1958;
Overgaauw, 1997) and 6 months (Webster, 1956).
However, prevalence studies in dogs worldwide have
assessed patent infections in adult dogs (Lloyd, 1993;
Barutzki and Schaper, 2003; Sager et al., 2006;
Martinez-Moreno et al., 2007). For adult canine hosts
it is recognised that patent infections can arise from
swallowing intestinal T. canis stages expelled by
puppies or from larvae in consumed paratenic hosts
like small prey animals (Warren, 1969; Saeed et al.,
2005). A few experiments with small numbers of
adult dogs infected with low numbers of embryonated
eggs resulted also in patent infections (Dubey, 1978;
Maizels and Meghji, 1984). It has been assumed that
this tracheal migration might be related to genetically
determined susceptibility or hormonal effects (Lloyd,
1998).
With the aim to elucidate the circumstances
under which adult dogs acquire patent infections by
ingesting embryonated eggs, we investigated the course
of experimental T. canis infections in immunologically
mature dogs with varied histories of previous exposure
to the parasite. In consideration of rising zoonotic
awareness and demand for regular, anthelmintic control
of patent infections in dogs, we also aimed to investigate
the effect of a regular anthelmintic treatment strategy on
the development of resistance or susceptibility to patent
infections.
2. Materials and methods
2.1. Animals
Eight male and ten female, facility-born crossbred
(Beagle  ‘Niederlaufhund’) dogs originating from
three litters, all aged 8–10 months at study day 0, were
included in the study. Half of the dogs were vertically
infected with T. canis and had proven patent infections
during puppyhood, as demonstrated by worm expulsion
after treatment with piperazine citrate (Stricker) at 5
weeks of age. The third litter consisting of nine dogs was
kept strictly T. canis-free by separation and application of
an intensive anthelmintic treatment scheme: the bitch
was administered Milbemax1 20 and 8 days ante partum
and 23 days post-partum. Her offspring were treated 2
and 4 weeks post-partum and then monthly with
Milbemax1 (tablets S, later M according to their
weight). From their 4th life week on, these dogs were
monitored coproscopically on a monthly basis and had
never shown positive results prior to the beginning of the
study. All animals were kept in groups of two to four dogs
of the same sex, housed in kennels of 6.5 m2 with 8 m2
runouts/two dogs, both with concrete floors and wooden
stands for rest, cleaned daily with high pressure cleaner at
80 8C (Ka¨rcher). They were fed commercially prepared
dried dog food and had access to tap water ad libitum.
Due to possible contamination with faeces containing
worm eggs, the positive control dogs (group 3, described
below) were kept isolated from all other animals in a part
of the building only accessible for a restricted number of
persons after changing clothes and boots. For cages and
boots, an ovocide disinfectant solution (Neopredisan
135-1, 2%, Vital Ag, Switzerland) was used in addition to
daily high pressure steam cleaning. Once they started
shedding eggs, the dogs were washed entirely with a
shampoo (Johnson) every second week to minimise
reinfection risk through eggs sticking on the hair coat.
Before the experiment started, all dogs received
anthelmintic treatment (Milbemax1, as described
below) and a general clinical examination was
performed. The experiment accorded to the Swiss
legislation on animal welfare and was authorised by the
animal experiment commission.
2.2. Experimental design
The course of treatments and egg inoculations in the
three experimental groups can be followed in Fig. 1.
Each six-dog group consisted of both genders and three
vertically T. canis-infected (subgroup a) and three
helminth-free (subgroup b) dogs.
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On study day 0, all 18 dogs were treated once with
Milbemax1. Dogs ofgroup 1 wereeachadministered 100
embryonated T. canis eggs (infections 1 and 2) on study
days 10 and 40, respectively, and Milbemax1 treatments
followed on study days 30 and 60, respectively (Fig. 1).
Dogs in group 2 were negative controls and got only
Milbemax1 treatments as described for group 1. Group 3
served as positive control group and got eggs as group 1,
but without any anthelmintic treatment. In the following
observation period from study days 60 to 150, none of the
participating animals received any eggs or anthelmintic
treatment. From study day 150 onwards, all groups were
given piperazine citrate on 3 consecutive days, allowing
the detection of excreted paralysed worms to prove or
rule out intestinal infections. On study day 160, all 18
dogs were administered 100 embryonated eggs (infection
3) to investigate the establishment of new patent infec-
tions despite previous intensive exposure to the parasite
(group 3), or after discontinuation of a regular frequent
macrocyclic lactone treatment with or without parasite
contact (groups 1 and 2, respectively). The infection was
followed by observation until study day 220.
2.3. Blood and serum samples (Haematology,
Serology)
Blood samples were drawn aseptically from the
jugular vein with sterile needles and evacuated EDTA
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Fig. 1. Specific serum antibody detection (IgG) in ELISA against T. canis larval E/S antigen in three groups of six dogs in the course of experimental
infection with 100 embryonated T. canis eggs (solid arrows) and anthelmintic treatment (radiating bodies). For all dogs, individual curves of ELISA
values are shown: (a) solid symbols: dogs with history of vertically transmitted patent T. canis infections; (b) open symbols: dogs kept helminth-free
prior to the beginning of the experiment. The cut-off was determined using 18 serum samples taken from the nine helminth-free dogs 2 and 3 months
before study start, respectively.
tubes (Vacuette1, Greiner bio-one). Sampling took
place in 10 days intervals during the first 80 study days
and biweekly for the rest of the study.
At the Clinical laboratory at Vetsuisse Faculty,
University of Zurich, differential blood cell counts were
carried out in 15–30 days intervals. For specific antibody
detection, a portion of the blood was centrifuged at
500  g for 10 min and the plasma aliquotted and stored
at 20 8C until it was used for ELISA.
2.4. Collection of faecal samples and coproscopic
examination
Once a week, dogs were housed separately overnight
and individual faecal samples were collected. A
combined sedimentation-floatation technique as
described (Eckert et al., 2005) with ZnCl2-solution
(density: 1.45) was carried out to identify patent
infections by detection of T. canis eggs. In order to
determine more exactly the prepatent periods, samples
were examined 3 times/week from study day 190 (30
days post-infection 3) onwards.
2.5. Anthelmintic treatment
Milbemax1 (Milbemycin oxime + Praziquantel,
Novartis) tablets size M were used for anthelmintic
treatment according to the manufacturer’s specifica-
tions. According to body weights of the dogs, the
administration of one tablet corresponded to 0.92–
1.56 mg of milbemycin oxime/kg body weight. For
treatment on day 150, Piperazine citrate (Piperazinzitrat
Stricker, Werner Stricker AG, Zollikofen, Switzerland)
was given with a dosage of 0.1 mg/kg on 3 consecutive
days.
2.6. Embryonated T. canis eggs and infection
To ensure a successful infection, each administration
of embryonated eggs took place 10 days after
anthelmintic treatments to exclude high residual levels
of active agents in the animals. T. canis eggs were
extracted from the uteri of adult female T. canis worms
from naturally infected beagle dogs kept in the
institute’s facilities. To embryonate, the eggs were
treated as described (Annen et al., 1975) and stored in
0.1 N H2SO4 at 4 8C before use. For administration,
eggs were washed in sterile phosphate buffered saline
solution (PBS) until pH had reached 6. For every
infection dose, 100 embryonated eggs were taken out
with a glass pipette under the microscope and mixed
with commercial moist cat food fed to the dogs.
2.7. Antibody detection ELISA
ELISA procedures were optimised with regard to
E/S antigen (larval T. canis excretory/secretory antigen
(de Savigny, 1975)) and conjugate dilutions. The
ELISA was carried out as described by Deplazes
et al. (1995), with the following modifications: E/S
antigen was diluted in 0.1 M carbonate/bicarbonate
coating buffer at 1:1000, and specific affinity purified,
alkaline phosphatase conjugated goat anti-dog IgG(g)
antibodies (KPL, Gaithersburg, MD, USA) were used at
a dilution of 1:800. All incubation steps were performed
at 37 8C for 1 h. Substrate (4-nitrophenyl phosphate
disodium salt hexahydrate (Fluka) in 0.05 M carbonate/
bicarbonate plus 1 mM MgCl buffer) was applied and
absorbance values at 405 nm (A405, reference filter
A630) were read 23 min later in a Multiscan RC ELISA
reader (Thermo Labsystems, Helsinki, Finland). Before
starting the test runs, several serum and plasma samples
taken in a preliminary test (simultaneously from the
same animals each) had been compared to ensure there
was no significant difference between serum and plasma
in ELISA results (data not shown). On every ELISA
plate, we included negative control sera from laboratory
dogs known to be free from nematodes and positive
control sera of dogs with proven experimental T. canis
infections (data not shown), as well as conjugate and
background controls. For cut-off determination, we
used samples taken from the nine T. canis-free dogs 2
and 3 months prior to study start. The cut-off was
calculated as mean + threefold standard deviation of the
absorbance values measured at 405 nm (A405).
3. Results
3.1. Development of patent infections
Following infections 1 and 2, no eggs were found in
the faeces of the dogs of groups 1 (infected and treated)
and 2 (treated only) and consequently, no worms were
recovered from their faeces following the piperazine
treatment on study day 150. In the infected but not
subsequently treated group 3, dogs with history of
vertically transmitted patent infections (subgroup 3a) as
well as previously Toxocara-free dogs (subgroup 3b)
became patent. No differences concerning the prepatent
periods of 42–56 days were found in these two
subgroups (Table 1). Weekly faecal examinations
revealed the ongoing patency. On study day 100 one
dog of subgroup 3a and on study day 108 a dog of
subgroup 3b spontaneously expulsed a part of the worm
burden; however, continuous egg excretion persisted in
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all six animals during the whole observation period
before treatment with piperazine on study day 150.
After the piperazine doses, adult worms were recovered
from the faeces of all dogs of group 3, and their faeces
remained egg free subsequent to this deworming until
infection 3 became patent.
Coproscopical examinations following infection 3
on study day 160 revealed the development of patent
infections in dogs of all three groups, as displayed in
Table 1. Patent infections were found in one dog of
group 1, exposed 3 times to eggs but treated with
Milbemax1 after the two first infections. This animal
belonged to the previously helminth-free subgroup 1b.
In group 2, which had not been experimentally exposed
to T. canis eggs until study day 160, two and three dogs
of subgroups ‘a’ and ‘b’, respectively, became patent
(Table 1). Finally, in group 3 which had presented patent
infection between study days 52 and 150, two dogs of
each subgroup showed patent infections again. Using
Fisher’s exact test to compare the results of infection 3,
group 1, with one out of six animals becoming patent,
was significantly different to group 2, with five out of
six patent animals ( p = 0.04 for a one tailed test). There
were neither significant differences between group 1
and group 3 nor between group 2 and group 3. Prepatent
periods of 40–55 days did not differ significantly
between the groups or after first or repeated infections
(for details, see Table 1). All animals with positive
coproscopical results were taken out of the study, and
five out of the eight animals that did not develop patent
infections were followed up until 100 days post-third
egg infection. During this time, no further patent
infections developed.
3.2. Specific antibody detection
To document larval invasion or parasite free status
during the study, all dogs were followed up in 10–14
days intervals for specific antibodies against larval E/S
antigens. Fig. 1 shows specific antibody reactions (IgG)
in the three experimental groups and subgroups. All
dogs of the helminth-free subgroups initially showed
ELISA values below the cut-off. However, four of the
nine dogs with history of vertically transmitted patent T.
canis infections showed low specific reactions at study
day 0. Higher specific antibody responses could be
detected 10 days post-infection 1 in all dogs of groups 1
and 3, whereas in group 1 values rose more sharply and
reached a higher level by study day 20 than those of
group 3. After study day 20, values of groups 1 and 3
converged to comparable levels. Antibody reaction
levels of the uninfected dogs (group 2) remained
significantly lower until day 160 of the study (Fig. 1).
After the infection on study day 160, moderately
increased reactions were seen in the previously infected
dogs (groups 1 and 3), and a sharp increase of specific
reactions in the previously non-infected control group 2.
One dog in group 2 suffered several times from fever
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Table 1
Development of patent T. canis infections in three groups of dogs with each two subgroups: (a) prior T. canis-exposed or (b) prior helminth-free dogs
Dogs were infected 1–3 times with 100 embryonated T. canis eggs. Groups 1 and 2 were treated on study days 30 and 60, and all groups were treated
on study day 150.
*1(a) Dogs with history of vertically transmitted infections that developed to patency as pups; (b) helminth-free dogs that had no contact to T. canis
until the beginning of the experiment. *2According to experimental design, no infection took place at the time point. *3Patent infection persisted from
first infection until anthelmintic treatment on day 150. *4Significant difference ( p < 0.05) between whole groups (n = 6).
and leukocytosis during the study. Absorbance values of
this animal always stayed visibly higher (Fig. 1,
subgroup 2a) as the group mates’ until study day 160
and increased less after the administration of embryo-
nated eggs.
3.3. Blood cell counts
Before being experimentally infected, the dogs had
not shown elevated eosinophilic counts at any time
point (data not shown). After each egg administration,
eosinophilic counts rose in all concerned dogs. Most
met or exceeded the reference value (1.29  103 ml1)
at 10 days post-infection (dpi), reaching highest counts
about 20 dpi (up to 6.56  103 ml1 in one group 2 dog
on study day 175) and dropping to normal by 30 dpi.
Eosinophilic counts did not differ in the subgroups ‘a’
and ‘b’ or in animals before or after reaching patency
compared to animals that did not develop patent
infections. Apart from increased eosinophils, there were
no significant changes detectable in the haemogram of
any dog throughout the study.
4. Discussion
The successful induction of patent T. canis infections
in adult dogs with and without previous exposure to the
parasite confirms the few earlier experimental data and
several observations in prevalence studies. Our results
support the hypothesis that the development of patent
infections beyond puppy age is more than coincidence
due to particular circumstances such as consumption of
infected paratenic hosts, immunosuppression, or hor-
monal changes. The age of our dogs of 8–10 months at
the beginning of the study was higher than the ‘‘age
resistance limit’’ indicated by various authors (Webster,
1956; Greve, 1971). When challenged by infection 3 of
the experiment, all dogs were older than a year. At this
age, the canine immune system is regarded as fully
competent (Felsburg, 2002).
To approximate the natural exposure of the canine
population to T. canis eggs in the field, we chose ‘‘low
dose’’ infections of just 100 embryonated eggs per
animal as described earlier (Overgaauw, 1997).
Actually, most experimentally induced intestinal infec-
tions in dogs employed a low number of eggs. Dubey
(1978) induced patent intestinal infections in 24 of 25
three-month-old dogs fed 10–1000 embryonated eggs,
but in none of 20 dogs administered 10,000 eggs. He
also found patent infections in three out of six adult
beagle dogs fed 100 eggs, but unlike our experiment, all
of them were T. canis-naı¨ve. Fernando (1968), Dubey
(1978) and Glickman et al. (1981) delivered evidence
that patent infections are less likely to develop after
infections with higher doses of eggs. However, Webster
(1956) published the establishment of infections in up to
6-month-old dogs after infection with large doses of
eggs. Lloyd et al. (1981) had a comparable success, but
only when treating a 6-month-old dog with corticoster-
oids. Additionally, the experimental animals used by the
two latter authors were still younger than ours. In a
reported case of repeated patent infections in three adult
male greyhounds with unknown history of previous
exposure and acquired immunity, the success of the
experiment was restricted to the particular susceptibility
of the breed and sex of the dogs and to the dose of
infective inoculum (100–200 eggs/infection) (Maizels
and Meghji, 1984). Partly, our results contradict this
opinion as we induced patent infections in another dog
breed and in both sexes. On the other hand, our results
confirm these authors’ opinion that the overall
susceptibility of adult dogs to patent T. canis infections
should be estimated at a higher level than so far
accepted.
In our age matched experimental groups, previous
exposure to vertical infections as well as experimentally
induced patent infections had no effect on reestablish-
ment of patent infections compared with helminth-free
animals. However, the observed trend suggests that
dogs with parasite contact and regular anthelmintic
treatment (group 1) are less likely to develop patent
infections following ingestion of eggs. This tendency of
developing a higher resistance might be explained by a
more pronounced immunological response against
antigens released by the destroyed migrating larvae
after milbemycin oxime treatment.
Increased specific antibody (IgG) reactions against
larval E/S antigens and eosinophilic counts from 10 dpi
on attest the infected dogs’ immune reaction patterns
after each inoculation with T. canis in our study.
Anthelmintic treatment did not inhibit the development
of characteristical immune mediated features in the
treated groups (groups 1 and 2) following infection.
This result implicates that the investigated antibody
reactions and increased eosinophilic counts, even
though proving immune functionality, are not necessa-
rily associated with protection against patent infections.
The control dog (group 2a) that had shown higher
specific reactions than its group mates and suffered
from intermittent fever and leukocytosis during the
study originated from the vertically infected subgroup.
We never found any clues relating to the causality of
these episodes. Necropsy of this dog (following
euthanasia after study termination) did not reveal any
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somatic damage, for instance by migrating larvae,
neither.
Prepatent periods for T. canis differ depending on the
route of infection, age of the host and inoculum size.
Puppies infected in utero can start to shed eggs less than
3 weeks after birth (Lloyd et al., 1983). For infection via
the lactogenic route, prepatency is about 4 weeks
(Stoye, 1976). Male and female dogs infected by
ingestion of paratenic hosts (mouse tissue containing T.
canis larvae) developed patent worm infections 34–48
dpi (Herschel, 1981). Concerning oral infections with
embryonated eggs, Dubey (1978) reported prepatencies
of 32–35 days in experimentally infected puppies
whereby he agrees with Glickman et al. (1981), who
described the onset of patency as 31–34 dpi in 2-month-
old beagles. Referring to the results of our study, and to
other authors, prepatency seems to be slightly extended
in older hosts. In 3-month-old dogs, Greve (1971) found
adult worms just in the intestines of dogs which he kept
for 35 or more days after infection. Saeed et al. (2005)
produced experimental intestinal T. canis infections in
14-month-old silver foxes when administering them
repeated doses of 400 embryonated eggs or larvae,
respectively, and found prepatencies of 33–41 days. All
in all, our results comprise 16 cases of onset of patency
with T. canis, and all of them developed between 40 and
56 dpi. Prepatency did not seem to be influenced by
previous T. canis exposure and immune response,
respectively.
Another resistance-related feature observed in this
study is expulsion of a part of the worm burden in two
dogs, one at 60 and one at 68 days after the second low
dose infection. This phenomenon has been described
earlier as a response to superinfection (Fernando, 1968).
Nevertheless, not all intestinal worms were eliminated
from both concerned dogs, as their coproscopic
examinations remained positive. Ongoing patency
was proven during 90 days in the six dogs of group 3
until anthelmintic treatment. A patent period of this
length accords to Schantz and Glickman (1981) who
determined the average life span of T. canis worms to be
4 months.
Puppies are quantitatively regarded as the main
shedders of T. canis eggs (Overgaauw, 1997; Lloyd,
1998). However, this group of dogs is more frequently
treated with anthelmintics and their environment is
more restricted. On the other hand, the epidemiological
and zoonotic impact of adult dogs should be recon-
sidered. Increasing fox populations even in urban areas
of central Europe (Deplazes et al., 2004; Reperant et al.,
2007) with high T. canis prevalences up to more than
70% maintain a constant infection pressure for the dog
population. Even if intestinal infections are not
associated with clinical disease in adult dogs, based
on the zoonotic potential, the guidelines of independent
international expert committees such as CAPC for the
United States (CAPC, 2007) or ESCCAP for Europe
(ESCCAP, 2007) recommend that the risk of patent
Toxocara infections in companion animals should be
minimised by more frequent treatment or regular
coproscopic testing. Protection against patent T. canis
infections can be achieved theoretically by continuous
anthelmintic treatment within the prepatent period.
Consequentially, based on the prepatent period
observed in this study, a regular treatment every 6
weeks would prevent most patent infections. A more
rigid concept with monthly administration of macro-
cyclic lactones as Dirofilaria immitis prophylaxis
suppresses nearly all canine nematodes, including
patent T. canis infections (Deplazes, 2006). As shown
in this study, such a continuous anthelmintic treatment
seems not to decrease the resistance to further patent
infections in dogs continuously exposed to T. canis
eggs.
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